Gener­ic drug in­dus­try calls on FTC to dig in­to monop­sony pow­er among buy­ers, PBMs

The gener­ic drug in­dus­try group is call­ing on the Fed­er­al Trade Com­mis­sion to crack down on monop­sony pow­er — or un­due mar­ket con­trol — ex­er­cised by drug buy­ing groups’ pur­chas­ing of gener­ic drugs, as well as an­ti-com­pet­i­tive prac­tices of the mid­dle­men known as phar­ma­cy ben­e­fit man­agers.

On the buy­ers’ side, three big com­pa­nies con­trol 92% of all whole­sale rev­enue, in­clud­ing Red Oak Sourc­ing (34%), Wal­greens Boots Al­liance (37%) and Claru­sOne/McKesson (21%), ac­cord­ing to the As­so­ci­a­tion of Ac­ces­si­ble Med­i­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER